Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Gossamer Bio (GOSS – Research Report) and keeping the price target at $6.00.
Joseph Schwartz’s rating is based on a combination of factors, including Gossamer Bio’s ongoing commitment to the PROSERA study for their drug seralutinib, which targets pulmonary arterial hypertension (PAH). The company is actively enrolling patients for this Phase 3 trial, with results expected by the end of 2025. This focus on a significant unmet need in the PAH market, as highlighted by recent surveys, supports the potential success of their treatment.
Additionally, despite previous challenges in the Phase 2 TORREY study, there were promising outcomes in severe cases, suggesting that Gossamer Bio could achieve positive results in the PROSERA study if they reach their target patient demographic. The company’s financial position, with substantial cash reserves expected to sustain operations into the first half of 2027, further strengthens the case for a Buy rating. Schwartz maintains a price target of $6, reflecting confidence in the company’s strategic direction and potential market impact.
In another report released on March 14, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.